Insider Trading

TBPH Stock

USD 9.61 0.36 3.61%

Under 71% of Theravance Biopharma's investor base is looking to short. The analysis of overall sentiment of trading Theravance Biopharma stock suggests that many investors are alarmed at this time. Theravance Biopharma's investing sentiment shows overall attitude of investors towards Theravance Biopharma.

November 19, 2024

Filed transaction by Theravance Biopharma Executive. Insider Public Trading

Read at macroaxis.com

Theravance insider trading alert for general transaction of by Kelly James Connor, Executive, on 19th of November 2024. This event was filed by Theravance Biopharma with SEC on 2023-04-11. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

Theravance Biopharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Theravance Biopharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.

Click cells to compare fundamentals

	Change To Inventory	Change In Cash	Stock Based Compensation	Free Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Net Income	Sale Purchase Of Stock
Change To Inventory		0.05	-0.37	0.33	-0.81	0.05	-0.25	0.2	0.16
Change In Cash	0.05		-0.24	-0.03	-0.3	-0.17	0.09	0.04	0.43
Stock Based Compensation	-0.37	-0.24		-0.6	0.62	-0.06	0.46	-0.77	-0.25
Free Cash Flow	0.33	-0.03	-0.6		-0.52	0.28	-0.16	0.67	-0.35
Depreciation	-0.81	-0.3	0.62	-0.52		-0.35	0.21	-0.28	-0.32
Other Non Cash Items	0.05	-0.17	-0.06	0.28	-0.35		0.37	-0.07	0.32
Capital Expenditures	-0.25	0.09	0.46	-0.16	0.21	0.37		-0.42	0.08
Net Income	0.2	0.04	-0.77	0.67	-0.28	-0.07	-0.42		-0.04
Sale Purchase Of Stock	0.16	0.43	-0.25	-0.35	-0.32	0.32	0.08	-0.04